FDA Greenlights Staar Surgical’s EVO Lens for Patients Aged 21-60, Unlocking 8M Customers
FDA approved Staar Surgical’s EVO/EVO+ Visian Implantable Collamer Lenses for patients aged 21 to 60, adding 8 million potential refractive customers and supported by three-year safety data showing a 1.25 safety index and 0.16% cataract incidence. Staar Surgical terminated its Alcon merger and appointed three new board members.
1. Expanded FDA Approval
The FDA approved an expanded indication for the EVO/EVO+ Visian Implantable Collamer Lenses to include patients aged 21 to 60, increasing the addressable U.S. refractive market by an estimated 8 million individuals.
2. Clinical Trial Safety Data
In a three-year clinical trial tracking 629 eyes, the EVO ICL achieved a safety index of 1.25, reported zero pupillary block or pigment dispersion cases, and observed a 0.16% anterior subcapsular cataract rate.
3. Merger Termination and Board Appointments
Staar Surgical and Alcon ended their merger agreement after failing to secure necessary stockholder votes, and the company appointed Neal Bradsher, Richard LeBuhn and Christopher Wang to its board of directors under a new cooperation agreement.
4. Stock Reaction and Technical Indicators
Shares are trading closer to 52-week lows, 9.8% below the 20-day SMA and 29.8% below the 100-day SMA, with an RSI at 22.35 indicating oversold conditions that could signal a potential buying opportunity.